Pilot Study to Examine Correlation of Nab-Paclitaxel/Gemcitabine Pharmacokinetics with Cachexia
P
Patrick Loehrer, MD
Primary Investigator
Overview
The purpose of this study is to examine the relationship between body composition (i.e. muscle and fat mass) and the side effects of treatment with a commonly used chemotherapy regimen, specifically nab-paclitaxel and gemcitabine, in patients with advanced, metastatic or recurrent pancreatic cancer.
Description
The purpose of this study is to examine the relationship between body composition (i.e. muscle and fat mass) and the side effects of treatment with a commonly used chemotherapy regimen, specifically nab-paclitaxel and gemcitabine, in patients with advanced, metastatic or recurrent pancreatic cancer.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
pancreatic cancer,Cancer cachexia
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
Patients with locally advanced, metastatic or recurrent pancreatic ductal adenocarcinoma (PDAC)
Planned systemic first or second line therapy with Nab-P/G
ECOG Performance Status 0-2
Ability to provide written informed consent and HIPAA authorization
Adequate organ function
Exclusion Criteria
Inability or refusal to receive systemic therapy
Refusal to permit the study team to obtain follow up information from treating physicians? office or perform in person or remote follow up on available records
Participants will be compensated for their participation.
Updated on
18 Apr 2024.
Study ID: 1709056266 (IUSCC-0632)